Stereotactic body radiation therapy for early non-small cell lung cancer

Frank Zimmermann, Jörn Wulf, Ingmar Lax, Yasushi Nagata, Robert D. Timmerman, Igor Stojkovski, Branislav Jeremic

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

For patients with early stage non-small cell lung cancer (NSCLC) unsuitable for resection local high-dose radiotherapy is the treatment of choice. In modern series even with escalated conformal radiotherapy local control rates of about 55% remain disappointing. Within the last years, stereotactic radiotherapy has been shown an effective treatment approach for early stage malignant lung tumors, combining the accurate focal dose delivery by stereotactic techniques with the biological advantages of dose escalated hypofractionated radiotherapy. Typical treatment regimens include three to five fractions over 1-2 weeks or 1 single fraction as radiosurgery. With adequate staging procedures including FDG-PET-CT scan and a low probability of subclinical involvement of unsuspicious locoregional lymph nodes, the concept is to irradiate the primary T1/2 tumor alone. Recent data report local control rates of up to 90%, with favorable results especially for patients in good general condition. Less than 10% of all patients develop isolated tumor recurrences in regional lymph nodes. Three-year survival is significantly improved to more than 80% when biological effective doses of more than 100 Gy are applied to patients in good conditions. Systemic tumor recurrence still is a major problem, making an additional systemic chemotherapy interesting for selected patients after hSRT, such as those younger than 75 years.

Original languageEnglish (US)
Pages (from-to)94-114
Number of pages21
JournalFrontiers of Radiation Therapy and Oncology
Volume42
DOIs
StatePublished - 2010

Fingerprint

Non-Small Cell Lung Carcinoma
Radiotherapy
Neoplasms
Lymph Nodes
Stereotaxic Techniques
Conformal Radiotherapy
Recurrence
Radiosurgery
Therapeutics
Drug Therapy
Lung
Survival

ASJC Scopus subject areas

  • Oncology
  • Radiology Nuclear Medicine and imaging

Cite this

Stereotactic body radiation therapy for early non-small cell lung cancer. / Zimmermann, Frank; Wulf, Jörn; Lax, Ingmar; Nagata, Yasushi; Timmerman, Robert D.; Stojkovski, Igor; Jeremic, Branislav.

In: Frontiers of Radiation Therapy and Oncology, Vol. 42, 2010, p. 94-114.

Research output: Contribution to journalArticle

Zimmermann, Frank ; Wulf, Jörn ; Lax, Ingmar ; Nagata, Yasushi ; Timmerman, Robert D. ; Stojkovski, Igor ; Jeremic, Branislav. / Stereotactic body radiation therapy for early non-small cell lung cancer. In: Frontiers of Radiation Therapy and Oncology. 2010 ; Vol. 42. pp. 94-114.
@article{31a4be71e5f1466ca316eef225adc3f3,
title = "Stereotactic body radiation therapy for early non-small cell lung cancer",
abstract = "For patients with early stage non-small cell lung cancer (NSCLC) unsuitable for resection local high-dose radiotherapy is the treatment of choice. In modern series even with escalated conformal radiotherapy local control rates of about 55{\%} remain disappointing. Within the last years, stereotactic radiotherapy has been shown an effective treatment approach for early stage malignant lung tumors, combining the accurate focal dose delivery by stereotactic techniques with the biological advantages of dose escalated hypofractionated radiotherapy. Typical treatment regimens include three to five fractions over 1-2 weeks or 1 single fraction as radiosurgery. With adequate staging procedures including FDG-PET-CT scan and a low probability of subclinical involvement of unsuspicious locoregional lymph nodes, the concept is to irradiate the primary T1/2 tumor alone. Recent data report local control rates of up to 90{\%}, with favorable results especially for patients in good general condition. Less than 10{\%} of all patients develop isolated tumor recurrences in regional lymph nodes. Three-year survival is significantly improved to more than 80{\%} when biological effective doses of more than 100 Gy are applied to patients in good conditions. Systemic tumor recurrence still is a major problem, making an additional systemic chemotherapy interesting for selected patients after hSRT, such as those younger than 75 years.",
author = "Frank Zimmermann and J{\"o}rn Wulf and Ingmar Lax and Yasushi Nagata and Timmerman, {Robert D.} and Igor Stojkovski and Branislav Jeremic",
year = "2010",
doi = "10.1159/000262465",
language = "English (US)",
volume = "42",
pages = "94--114",
journal = "Frontiers of Radiation Therapy and Oncology",
issn = "0071-9676",
publisher = "S. Karger AG",

}

TY - JOUR

T1 - Stereotactic body radiation therapy for early non-small cell lung cancer

AU - Zimmermann, Frank

AU - Wulf, Jörn

AU - Lax, Ingmar

AU - Nagata, Yasushi

AU - Timmerman, Robert D.

AU - Stojkovski, Igor

AU - Jeremic, Branislav

PY - 2010

Y1 - 2010

N2 - For patients with early stage non-small cell lung cancer (NSCLC) unsuitable for resection local high-dose radiotherapy is the treatment of choice. In modern series even with escalated conformal radiotherapy local control rates of about 55% remain disappointing. Within the last years, stereotactic radiotherapy has been shown an effective treatment approach for early stage malignant lung tumors, combining the accurate focal dose delivery by stereotactic techniques with the biological advantages of dose escalated hypofractionated radiotherapy. Typical treatment regimens include three to five fractions over 1-2 weeks or 1 single fraction as radiosurgery. With adequate staging procedures including FDG-PET-CT scan and a low probability of subclinical involvement of unsuspicious locoregional lymph nodes, the concept is to irradiate the primary T1/2 tumor alone. Recent data report local control rates of up to 90%, with favorable results especially for patients in good general condition. Less than 10% of all patients develop isolated tumor recurrences in regional lymph nodes. Three-year survival is significantly improved to more than 80% when biological effective doses of more than 100 Gy are applied to patients in good conditions. Systemic tumor recurrence still is a major problem, making an additional systemic chemotherapy interesting for selected patients after hSRT, such as those younger than 75 years.

AB - For patients with early stage non-small cell lung cancer (NSCLC) unsuitable for resection local high-dose radiotherapy is the treatment of choice. In modern series even with escalated conformal radiotherapy local control rates of about 55% remain disappointing. Within the last years, stereotactic radiotherapy has been shown an effective treatment approach for early stage malignant lung tumors, combining the accurate focal dose delivery by stereotactic techniques with the biological advantages of dose escalated hypofractionated radiotherapy. Typical treatment regimens include three to five fractions over 1-2 weeks or 1 single fraction as radiosurgery. With adequate staging procedures including FDG-PET-CT scan and a low probability of subclinical involvement of unsuspicious locoregional lymph nodes, the concept is to irradiate the primary T1/2 tumor alone. Recent data report local control rates of up to 90%, with favorable results especially for patients in good general condition. Less than 10% of all patients develop isolated tumor recurrences in regional lymph nodes. Three-year survival is significantly improved to more than 80% when biological effective doses of more than 100 Gy are applied to patients in good conditions. Systemic tumor recurrence still is a major problem, making an additional systemic chemotherapy interesting for selected patients after hSRT, such as those younger than 75 years.

UR - http://www.scopus.com/inward/record.url?scp=77949416796&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77949416796&partnerID=8YFLogxK

U2 - 10.1159/000262465

DO - 10.1159/000262465

M3 - Article

C2 - 19955796

AN - SCOPUS:77949416796

VL - 42

SP - 94

EP - 114

JO - Frontiers of Radiation Therapy and Oncology

JF - Frontiers of Radiation Therapy and Oncology

SN - 0071-9676

ER -